chronic inflammation, as one way in which early stages of disease might lower TC. However, occult disease causing low TC does not rule out the possibility that low TC is an aggravating factor in disease processes. The hypothesis of Manolio et al and of Harris et al, 6 that there are two groups of people with low TC, one healthy and the other diseased, is conceptually attractive yet difficult to address because there is no sure way to identify the source of a given individual's low TC. Iribarren et al found elevated total mortality at low TC levels in the Honolulu Heart Program only in the 23% of participants who at baseline were heavy drinkers or smokers or had medical conditions such as gastrectomy, liver cirrhosis, colectomy, or intestinal disease (Iribarren C, Dwyer JH, Burchfiel CM, Reed DM: Can the U-shaped relation between mortality and serum cholesterol be explained by confounding? Submitted to the American Heart Association's 33rd Annual Conference on Cardiovascular Disease Epidemiology, March 17-20, 1993, Santa Fe, N.M.).
Another approach to understanding the observed low-TC-disease associations is to consider plausible mechanisms. Konishi and colleagues37 make a cogent argument that low TC plays a causal role in hemorrhagic stroke; they propose that low TC fosters degenerative change in intracerebral arterioles through increased fragility of media muscle cells. Low TC can modify levels of cell membrane cholesterol7-9 and thereby modify membrane permeability to toxins and influence cell and membrane products. One cell product, for example, pulmonary surfactant, may be susceptible to modification at low TC levels because it derives much of its cholesterol from plasma low and high density lipoprotein.10,' Cell membrane abnormalities occur in many diseases, but it is not clear whether low TC contributes. A causal role for low TC in some diseases, therefore, remains a plausible but unproven hypothesis.
It may be that TC-disease associations differ between the elderly versus the middle-aged. Manolio Mortality change for middle-aged men was modeled under these four possible shifts of the population TC distribution and under several assumptions about the causal effects of TC change, using the cardiovascular disease, noncardiovascular disease, and total mortality rates (per 10,000 in 6 years) for the 10 classes of TC observed in the men screened.3 Rates were smoothed and extrapolated to a TC level of 110 mg/dl. Modeled mortality rates were computed as a weighted average of the death rate at the new TC level (after the change represented by one of the four distributions) and the death rate at the observed TC level. The death rate at the new TC level was weighted by the causality proportion (for example, 0.2 representing 20% causality), and the death rate at the observed TC level was weighted by its complement, (1-the causality proportion). The causality proportion was taken to be 1 for cardiovascular disease.
We examined the predicted effects of each of these population shifts in TC distribution on cardiovascular, noncardiovascular, and total mortality under these several scenarios with added assumptions of different degrees of causality for low TC level and noncardiovascular diseases (100%, 50%, and 20%).
Modeled Public Health Impact All models predicted similar substantial decreases in cardiovascular disease mortality. The "worst-case" model predicted an increase of 0.2% in total mortality, assuming full causality of lowered TC on noncardiovascular deaths and a uniform shift downward of 20 mg/dl in TC across the entire distribution. An assumption of less than full causality for noncardiovascular disease death reduced the estimated increase in noncardiovascular mortality associated with TC lowering and yielded a 3.1% decline in total mortality. However, models that do not take into account proportionate change in TC levels when average population levels fall exaggerate the potential untoward effects of TC-lowering strategies. Modeling a proportionate shift downward in population TC levels damps the predicted increase in noncardiovascular disease death, resulting in estimated net reductions in total mortality of 4.2% under the 100% low-TC causality assumption and 5.8% or 6 assumed, the total mortality reduction of 6.7% in the model in which people with low TC levels increase their values is somewhat less favorable than the 6.9% reduction in the corresponding model in which people with low TC levels experience a proportionate decrease in TC level. All these models were based on a sample of middle-aged men having mean TC of 215 mg/dl. A cautionary note is that the lower the population TC among men, the less is the predicted overall population benefit from TC lowering.
We consider closest to reality the models of proportionate decline in TC level along with 50% or 20% causality of TC lowering on noncardiovascular deaths. These models predict declines in total mortality rate consistent with the declines actually observed in recent decades in the United States'8 as population means of TC and other cardiovascular risk factors have declined. 19, 20 Such models may be helpful in thinking about future public health strategies for reduction of atherosclerotic diseases. The proportionate TC change and partial causality models imply that little harm is done to those having low TC by the current, population-wide TC lowering strategies, because already low TC levels are relatively little changed by such population strategies and because only part of the association between low TC and mortality is likely to be causal. Models that do not further alter a low TC level imply that a slight improvement in overall mortality rate might be achieved if people with such levels make no further eating pattern changes or relax changes already made. Models in which TC is actually increased in those with low TC represent a medical strategy that has a strong advantage only if 100% causality holds. Individual efforts to actively increase a low TC are unlikely to undermine the current effective population strategy of gradual TC lowering. But neither are they likely, at this stage of knowledge, to be deemed an appropriate medical strategy. Women For women, the evidence suggests that the pattern of the relation between TC and various noncardiovascular diseases is similar to that in men, although absolute rates for women are lower; to this extent, these models apply to women. The important exception, however, is the flat relation between TC and mortality from total cardiovascular disease in women despite an equally strong relation among sexes of coronary heart disease mortality to TC. For example, there are diet effects on obesity, and many conditions are likely to be affected favorably by the recommended increased intake of antioxidants and fibers. Because current population-wide efforts to lower high average TC levels in Western nations clearly have benefit in reducing cardiovascular disease morbidity and mortality and, as we show here, have relatively little estimated impact on noncardiovascular disease mortality, those public health strategies for lowering TC will probably continue to benefit populations having mass (relative) hypercholesterolemia. Although there are no clinical data indicating harm from lowering already low TC levels, the theoretically greater risk for nonatherosclerotic diseases could outweigh the small absolute reduction in coronary heart disease risk. Therefore, it appears reasonable that individuals found to have low TC values take no specific steps to further lower their personal levels.
